Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: The fetal compartment (placenta and amniotic fluid)

Antiviral Therapy

Volumn 16, Issue 8, 2011, Pages 1139-1147

  Else, Laura J ^a   Taylor, Stephen ^b   Back, David J ^a   Khoo, Saye H ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

DRUG ABSORPTION; DRUG ACCUMULATION; DRUG AMNION FLUID LEVEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG TRANSPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PLACENTAL TRANSFER; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE;

ADENINE; ADULT; AMNIOTIC FLUID; ANTI-HIV AGENTS; CYCLOHEXANES; FEMALE; FETAL BLOOD; FETUS; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; NEVIRAPINE; PEPTIDE FRAGMENTS; PHOSPHONIC ACIDS; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRROLIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; TRIAZOLES; VIRAL LOAD; ZIDOVUDINE;

EID: 83455206864     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1918     Document Type: Review

References (117)

1. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973-981. (Pubitemid 351652248)
2. Hill MD, Abramson FP. The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state. Clin Pharmacokinet 1988; 14:156-170.
3. Ward RM. Drug therapy of the fetus. J Clin Pharmacol 1993; 33:780-789. (Pubitemid 23289668)
4. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004; 43:487-514. (Pubitemid 38858303)
5. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-494. (Pubitemid 34456340)
6. Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis 2001; 183:539-545. (Pubitemid 32147509)
7. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335:1621-1629. (Pubitemid 26392726)
8. Taylor S, Davies S. Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV. Curr Opin HIV AIDS 2010; 5:335-343.
9. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591-601. (Pubitemid 351650540)
10. Patterson TA, Binienda ZK, Newport GD, et al. Transplacental pharmacokinetics and fetal distribution of 2′, 3′-didehydro- 3′-deoxythymidine (d4T) and its metabolites in late-term rhesus macaques. Teratology 2000; 62:93-99. (Pubitemid 30614363)
11. Tuntland T, Odinecs A, Pereira CM, Nosbisch C, Unadkat JD. In vitro models to predict the in vivo mechanism, rate, and extent of placental transfer of dideoxynucleoside drugs against human immunodeficiency virus. Am J Obstet Gynecol 1999; 180:198-206. (Pubitemid 29088415)
12. Schenker S, Johnson RF, King TS, Schenken RS, Henderson GI. Azidothymidine (zidovudine) transport by the human placenta. Am J Med Sci 1990; 299:16-20. (Pubitemid 20052878)
13. Henderson GI, Perez AB, Yang Y, Hamby RL, Schenken RS, Schenker S. Transfer of dideoxyinosine across the human isolated placenta. Br J Clin Pharmacol 1994; 38:237-242. (Pubitemid 24282744)
14. Bloom SL, Dias KM, Bawdon RE, Gilstrap LC, III. The maternal-fetal transfer of lamivudine in the ex vivo human placenta. Am J Obstet Gynecol 1997; 176:291-293. (Pubitemid 27107911)
15. Casey BM, Bawdon RE. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am J Obstet Gynecol 1998; 179:758-761. (Pubitemid 28447260)
16. Watts DH, Brown ZA, Tartaglione T, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis 1991; 163:226-232.
17. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178:1327-1333.
18. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187:725-735. (Pubitemid 36286932)
19. Chappuy H, Treluyer JM, Jullien V, et al. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48:4332-4336. (Pubitemid 39434895)
20. Siu SS, Yeung JH, Pang MW, Chiu PY, Lau TK. Placental transfer of Zidovudine in first trimester of pregnancy. Obstet Gynecol 2005; 106:824-827. (Pubitemid 41362190)
21. Moisan A, Desnoyer A, Bourgeois-Moine A, et al. Placental transfer of antiretroviral drugs in HIV-infected women: a retrospective study from 2002 to 2009. 11th International Workshop on Clinical Pharamcology of HIV Therapy. 7-9 April 2010, Sorrento, Italy. Abstract 1.
22. Yeh RF, Rezk NL, Kashuba AD, et al. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother 2009; 53:2367-2374.
23. Mandelbrot L, Peytavin G, Firtion G, Farinotti R. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol 2001; 184:153-158. (Pubitemid 32141658)
24. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180. (Pubitemid 24331334)
25. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802. (Pubitemid 29415583)
26. Gazzard BG, Anderson J, Babiker A, et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9:563-608.
27. European AIDS Clinical Society. Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe. June 2008. (Accessed 28 September 2010.) Available from www.europeanaidsclinicalsociety.org/ guidelinespdf/1-Treatmentof-HIV-Infected-Adults.pdf
28. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant women for maternal health and interventions to reduce perinatal HIV transmission in the United States. (Updated May 2010. Accessed 28 September 2010.) Available from http://aidsinfo.nih.gov/ contentfiles/PerinatalGL.pdf
29. de Ruiter A, Mercey D, Anderson J, et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008; 9:452-502.
30. Clark TN, White CA, Bartlett MG. Determination of didanosine in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2006; 20:605-611. (Pubitemid 44043405)
31. Wade N, Unadkat J, Huang S, et al. Pharmacokinetics and safety of d4T and 3TC in HIV-infected pregnant women and their infants (PACTG 332). 10th Conference on Retroviruses and Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract 886.
32. Bonora S, Gonzalez de Requena D, Chiesa E, et al. Transplacental passage of tenofovir and other antiretrovirals at delivery. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2010, Los Angeles, CA, USA. Abstract 738a.
33. Burchett S, Best B, Mirochnick M, et al. Tenofovir pharmacokinetics during pregnancy, at delivery and postpartum. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2010, Los Angeles, CA, USA. Abstract 738b.
34. Rodman J, Flynn P, Shapiro D, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate in HIV-1-infected pregnant women and their infants. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2010, Denver, CO, USA. Abstract 708.
35. Flynn P, Mirochnick M, Shapiro D, et al. Single dose tenofovir disoproxil fumarate (TDF) with and without emtricitabine (FTC) in HIV-1 infected pregnant women and their infants: pharmacokinetics (PK) and safety. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 939.
36. Mirochnick M, Kafulafula G, Kreitchmann R, et al. Pharmacokinetics (PK) of tenofovir disoproxil fumarate (TDF) after administration to HIV-1 infected pregnant women and their newborns. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 137.
37. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007; 370:1698-1705. (Pubitemid 350100773)
38. Best B, Stek A, Hu C, et al. High-dose lopinavir and standard-dose emtricitabine pharmacokinetics during pregnancy and post-partum. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 629.
39. Hirt D, Urien S, Rey E, et al. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother 2009; 53:1067-1073.
40. Bennetto-Hood C, Bryson YJ, Stek A, King JR, Mirochnick M, Acosta EP. Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. HIV Clin Trials 2009; 10:41-47.
41. Musoke P, Guay LA, Bagenda D, et al. A Phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13:479-486.
42. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178:368-374. (Pubitemid 28347918)
43. Gingelmaier A, Kurowski M, Kastner R, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006; 20:1737-1743. (Pubitemid 44299365)
44. Capparelli EV, Aweeka F, Hitti J, et al. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med 2008; 9:214-220. (Pubitemid 351467794)
45. Ivanovic J, Nicastri E, Anceschi MM, et al. Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Curr HIV Res 2009; 7:620-625.
46. Ivanovic J, Viscione M, Nicastri E, et al. TDM of antiretroviral drugs inHIV-infected pregnant women: transplacental diffusion, newborn clinical status and maternal immuno-virological outcome. 11th International Workshop on Clinical Pharamcology of HIV Therapy. 7-9 April 2010, Sorrento, Italy. Abstract 14.
47. Arrivé E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36:1009-1021. (Pubitemid 350018545)
48. Nightingale SL. From the Food and Drug Administration. JAMA 1998; 280:1472.
49. Chersich MF, Urban MF, Venter FW, et al. Efavirenz use during pregnancy and for women of child-bearing potential. AIDS Res Ther 2006; 3:11.
50. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37:3594-3601. (Pubitemid 28162914)
51. Srinivas RV, Middlemas D, Flynn P, Fridland A. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 1998; 42:3157-3162. (Pubitemid 28553735)
52. Marzolini C, Rudin C, Decosterd LA, et al. Transplacental passage of protease inhibitors at delivery. AIDS 2002; 16:889-893. (Pubitemid 34409012)
53. Mirochnick M, Dorenbaum A, Holland D, et al. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 2002; 21:835-838.
54. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931-1939. (Pubitemid 44427610)
55. Chappuy H, Treluyer JM, Rey E, et al. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 2004; 191:558-562. (Pubitemid 39178714)
56. Capparelli E, Stek A, Best B, et al. Boosted fosamprenavir pharmacokinetics during pregnancy. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 908.
57. Lechelt M, Lyons F, Clarke A, Magaya V, Issa R, de Ruiter A. Human placental transfer of atazanavir: a case report. AIDS 2006; 20:307.
58. Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007; 21:2409-2415. (Pubitemid 350145172)
59. Conradie F, Zorilla C, Josipovic D, et al. The saftey, efficacy and steady state pharmacokinetics of atazanavir/ritonavir (ATV/r) once daily given in combination with twice daily AZT/3TC during pregnancy: results of study AI424182. 5th IAS Conference on HIV Pathogenesis and Treatment. 19-22 July 2009, Cape Town, South Africa. Abstract LBPEB06.
60. Best BM, Stek AM, Mirochnick M, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2010; 54:381-388.
61. Soric M, Gingelmaier A, Kaestner R, et al. A German cohort of 54 HIV and LPV/r exposed pregnancies-pharmacokinetics, placental transfer and pregnancy outcome. XVII International AIDS Conference. 3-8 August 2008, Mexico City, Mexico. Abstract CDB0204.
62. Ripamonti D, Cattaneo D, Cortinovis M, Maggiolo F, Suter F. Transplacental passage of ritonavir-boosted darunavir in two pregnant women. Int J STD AIDS 2009; 20:215-216.
63. Ivanovic J, Bellagamba R, Nicastri E, et al. Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety. AIDS 2010; 24:1083-1084.
64. Pinnetti C, Tamburrini E, Ragazzoni E, De Luca A, Navarra P. Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1. Antivir Ther 2010; 15:127-129.
65. Best B, Caparelli E, Stek A, et al. Raltegravir pharmacokinetics during pregnancy. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. 12-15 September 2010, Boston, MA, USA. Abstract H-1668a.
66. McKeown DA, Rosenvinge M, Donaghy S, et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS 2010; 24:2416-2418.
67. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999; 36:439-452. (Pubitemid 29317491)
68. Gow PJ, Ghabrial H, Smallwood RA, Morgan DJ, Ching MS. Neonatal hepatic drug elimination. Pharmacol Toxicol 2001; 88:3-15. (Pubitemid 32113216)
69. Winters MA, Van Rompay KK, Kashuba AD, Shulman NS, Holodniy M. Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. Antimicrob Agents Chemother 2010; 54:4059-4063.
70. Ceccaldi PF, Ferreira C, Gavard L, Gil S, Peytavin G, Mandelbrot L. Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model. Am J Obstet Gynecol 2008; 198:433.e1-2.
71. Brennan-Benson P, Pakianathan M, Rice P, et al. Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. AIDS 2006; 20:297-299.
72. Ghosn J, Chaix ML, Peytavin G, et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 2004; 18:1958-1961. (Pubitemid 39313214)
73. Furco A, Gosrani B, Nicholas S, et al. Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS 2009; 23:434-435.
74. Sastry BV. Techniques to study human placental transport. Adv Drug Deliv Rev 1999; 38:17-39. (Pubitemid 29216951)
75. Bourget P, Roulot C, Fernandez H. Models for placental transfer studies of drugs. Clin Pharmacokinet 1995; 28:161-180.
76. Garland M. Pharmacology of drug transfer across the placenta. Obstet Gynecol Clin North Am 1998; 25:21-42. (Pubitemid 28141699)
77. Nau H, Luck W, Kuhnz W. Decreased serum protein binding of diazepam and its major metabolite in the neonate during the first postnatal week relate to increased free fatty acid levels. Br J Clin Pharmacol 1984; 17:92-98. (Pubitemid 14054618)
78. Krauer B, Dayer P, Anner R. Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs. Br J Obstet Gynaecol 1984; 91:875-881. (Pubitemid 14033846)
79. Wood M, Wood AJ. Changes in plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant. Clin Pharmacol Ther 1981; 29:522-526. (Pubitemid 11039807)
80. Hamar C, Levy G. Serum protein binding of drugs and bilirubin in newborn infants and their mothers. Clin Pharmacol Ther 1980; 28:58-63. (Pubitemid 10090686)
81. Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL. Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma. Br J Clin Pharmacol 2007; 63:315-321.
82. Gavard L, Gil S, Peytavin G, et al. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am J Obstet Gynecol 2006; 195:296-301. (Pubitemid 43927527)
83. Nanovskaya T, Deshmukh S, Brooks M, Ahmed MS. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther 2002; 300:26-33. (Pubitemid 34028504)
84. Kim AE, Dintaman JM, Waddell DS, Silverman JA. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998; 286:1439-1445. (Pubitemid 29135560)
85. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14:237-242. (Pubitemid 30132917)
86. Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, Polli JW. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001; 29:754-760. (Pubitemid 32374579)
87. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007; 73:1573-1581. (Pubitemid 46527547)
88. Gerk PM, Vore M. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther 2002; 302:407-415. (Pubitemid 34787202)
89. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998; 58:5337-5339. (Pubitemid 28551112)
90. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38:1277-1287. (Pubitemid 20266126)
91. Sugawara I, Kataoka I, Morishita Y, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988; 48:1926-1929.
92. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 1999; 104:1441-1447.
93. Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL. Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus. Br J Clin Pharmacol 2008; 65:667-673. (Pubitemid 351535077)
94. Mölsä M, Heikkinen T, Hakkola J, et al. Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther 2005; 78:123-131. (Pubitemid 41112280)
95. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 2001; 59:806-813. (Pubitemid 32274009)
96. St-Pierre MV, Serrano MA, Macias RI, et al. Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 2000; 279:R1495-R1503.
97. Flens MJ, Zaman GJ, van der Valk P, et al. Tissue distribution of the multidrug resistance protein. Am J Pathol 1996; 148:1237-1247. (Pubitemid 26111082)
98. Janneh O, Anwar T, Jungbauer C, et al. P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. Antivir Ther 2009; 14:965-974.
99. Huisman MT, Smit JW, Crommentuyn KM, et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002; 16:2295-2301. (Pubitemid 35449015)
100. Mirochnick M. Antiretroviral pharmacology in pregnant women and their newborns. Ann N Y Acad Sci 2000; 918:287-297.
101. Hakkola J, Raunio H, Purkunen R, et al. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem Pharmacol 1996; 52:379-383. (Pubitemid 26233768)
102. Koskela S, Hakkola J, Hukkanen J, et al. Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol 1999; 57:1407-1413. (Pubitemid 29225104)
103. Pasanen M, Helin-Martikainen HL, Pelkonen O, Kirkinen P. Intrahepatic cholestasis of pregnancy impairs the activities of human placental xenobiotic and steroid metabolizing enzymes in vitro. Placenta 1997; 18:37-41. (Pubitemid 27105508)
104. McRobie DJ, Glover DD, Tracy TS. Effects of gestational and overt diabetes on human placental cytochromes P450 and glutathione S-transferase. Drug Metab Dispos 1998; 26:367-371. (Pubitemid 28201248)
105. Aherne W, Dunnill MS. Morphometry of the human placenta. Br Med Bull 1966; 22:5-8.
106. Kaufmann P, Scheffen I. Placental development. Philadelphia: Saunders, WB 1992; pp. 47-56.
107. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193:1195-1201.
108. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21:1019-1026. (Pubitemid 46684333)
109. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:380-387.
110. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346:1863-1870. (Pubitemid 34603030)
111. Briand N, Mandelbrot L, Le Chenadec J, et al. No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS 2009; 23:1235-1243.
112. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007; 21:607-615.
113. Ekouevi DK, Coffie PA, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire. AIDS 2008; 22:1815-1820.
114. Floridia M, Ravizza M, Bucceri A, et al. Factors influencing gestational age-adjusted birthweight in a national series of 600 newborns from mothers with HIV. HIV Clin Trials 2008; 9:287-297.
115. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 2000; 25:261-268.
116. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354:1084-1089. (Pubitemid 29452821)
117. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17:1769-1785. (Pubitemid 37000095)